BETA: Please send your feedback!
IPG Photonics
IPGP:NAS
Electronic Equipment/Instruments
$6.29bn
LARGE cap
$118.30
(-6.43%)
0.04%
since start of 2019
20.75
- —
- —
- —
- —
- —
- —
- —
- —
- —
- —
- —
- 3
-
CF
-
PP
-
WC
-
DP
-
CH
-
ES
-
WS
-
CG
-
EP
-
CM
-
FL
-
GD
- —
- 1
- 2
- 3
- 4
- 5
About
Biotechnology
Founded 1997
Seattle Genetics, Inc. engages in the development and commercialization of monoclonal antibody-based therapies for cancer. Its product ADCETRIS, is an antibody-drug conjugate comprising an anti-CD30 monoclonal antibody attached by a protease-cleavable linker to a microtubule disrupting agent, monomethyl auristatin E. The company was founded by Clay B. Siegall and H. Perry Fell on July 15, 1997 and is headquartered in Bothell, WA.
website
Headquarters
Executives
| Name | Title | Gender |
| Eugene A. Shcherbakov, PhD, DSc | COO, Director & SVP-Europe Region | Male |
| Valentin P. Gapontsev, PhD | Chairman & Chief Executive Officer | Male |
| Timothy P. V. Mammen | Chief Financial Officer & Senior Vice President | Male |
| James F. Hillier | Vice President-Investor Relations | Male |
| Angelo P. Lopresti | Secretary, Senior Vice President & General Counsel | Male |
| Igor Samartsev | Director & Chief Technology Officer | Male |
| Tom Burgomaster | Treasurer, Vice President & Corporate Controller | Male |
Mindful Investing Summary
- —
- 1
- 2
- 3
- 4
- 5
-
Carbon Footprint — N/A
-
Pollution Prevention — N/A
-
Water Conservation — N/A
-
Data & Privacy Protection — N/A
-
Consumer Health, Wellness & Safety — N/A
-
Employee Ownership, Satisfaction, Benefits & Pay — N/A
-
Workplace Health and Safety — N/A
-
Integrity of Corporate Governance — N/A
-
Ethical Practices — N/A
-
Usage of Conflict Materials — N/A
-
Forced Labor — N/A
-
Diversity of Corporate Leadership 3
Seattle Genetics - Competitors and Related Companies
How Seattle Genetics stacks up to its peers in the Biotechnology industry or with competing business segments.
Seattle Genetics
SGEN:NAS
Biotechnology
$12.88bn
MID cap
$76.28
(-2.08%)
0.34%
since start of 2019
-43.80
Loading…